13F filing recap · Q2 2025
What did Patient Capital Management buy in Q2 2025?
Reported stock-position changes between this filing and the previous one.
Stock value
$2.22B
Positions
40
Estimated turnover
17.1%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Patient Capital Management opened new positions in UnitedHealth Group, Tempus Ai, Noble Corporation, and Angi, while exiting Brilliant Earth Group, Carvana, and New Fortress Energy. The firm trimmed Qxo, Norwegian Cruise Line, Energy Transfer, Sofi Technologies, Biogen, General Motors, Mattel, and Canada Goose, with the latter three seeing substantial reductions. Notable additions included Illumina, Seadrill, and Delta Air Lines.